Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1081. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal haemorrhage

The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal haemorrhage The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal haemorrhage The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal haemorrhage Targownik L E, Spiegel B M, Dulai G S, Karsan H A, Gralnek I M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three strategies for the prevention of recurrent variceal haemorrhage (RVH) were evaluated. Option 1 was endoscopic band ligation (EBL). Option 2 was combination medical therapy with nadolol and isosorbide-5-mononitrate, without hepatic venous pressure

NHS Economic Evaluation Database.2004

1082. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand

What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand Sheerin I G, Green F T, Sellman J D Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment for hepatitis C virus (HCV) was assessed using either conventional combination therapy (CCT; alpha-interferon combined with ribavirin) or combination therapy with pegylated interferon (PEG) in injecting drug users (IDUs) on methadone maintenance therapy (MMT). Type

NHS Economic Evaluation Database.2004

1083. Screening for hepatitis C in injecting drug users: a cost utility analysis

Screening for hepatitis C in injecting drug users: a cost utility analysis Screening for hepatitis C in injecting drug users: a cost utility analysis Screening for hepatitis C in injecting drug users: a cost utility analysis Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The screening for, and diagnosis and treatment of hepatitis C virus (HCV) were considered. Screening comprised a combination of enzyme-linked immunosorbent assay (ELISA) followed by a polymerase chain reaction (PCR) to confirm the presence of HCV ribonucleic acid (RNA). Individuals who were HCV RNA positive were offered a liver biopsy to determine eligibility for treatment. Treatment comprised

NHS Economic Evaluation Database.2004

1084. Screening for hepatitis C in injecting drug users: a cost utility analysis

Screening for hepatitis C in injecting drug users: a cost utility analysis Screening for hepatitis C in injecting drug users: a cost utility analysis Screening for hepatitis C in injecting drug users: a cost utility analysis Stein K, Dalzel K, Walker A, Jenkins B, Round A, Royle P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for hepatitis C virus (HCV) using an enzyme-linked immunosorbant assay (ELISA), followed by polymerase chain reaction (PCR) to confirm the presence of HCV ribonucleic acid (RNA), was studied. Type of intervention Screening. Economic study type Cost-utility analysis. Study population The hypothetical target population comprised people with a history of injecting drug use whom were

NHS Economic Evaluation Database.2004

1085. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C Lin O S, Keeffe E B, Sanders G D, Owens D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for hepatocellular carcinoma (HCC) in patients with chronic hepatitis C and compensated cirrhosis was assessed. The strategies used combined abdominal ultrasonography (US) or computerised tomography (CT) with serum alpha-foetoprotein (AFP) at 6 to 12 month intervals. Type

NHS Economic Evaluation Database.2004

1086. Screening in chronic hepatitis B carriers: a retrospective study in a primary care clinic

Screening in chronic hepatitis B carriers: a retrospective study in a primary care clinic Screening in chronic hepatitis B carriers: a retrospective study in a primary care clinic Screening in chronic hepatitis B carriers: a retrospective study in a primary care clinic Kung K, Lam A, Li P K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study examined alpha-fetoprotein (AFP), alanine transaminase (ALT) and ultrasonography (USG) screening programmes. All of which were common practices in the authors' setting to detect cirrhosis or hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) carriers. The cut-off value for abnormal AFP adopted in the study was larger than 7 mg/L. Type of intervention

NHS Economic Evaluation Database.2004

1087. Treatment with pegylated interferon in hepatitis C

Treatment with pegylated interferon in hepatitis C Treatment with pegylated interferon in hepatitis C Treatment with pegylated interferon in hepatitis C Cernadas C, Pichon Riviere A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cernadas C, Pichon Riviere A, Garcia Marti S. Treatment with pegylated interferon in hepatitis (...) C. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives The aim of this report was to investigate treatment with pegylated interferon in hepatitis C Authors' conclusions It is important to bear in mind that the results from the reports published refer, in general, to intermediate end-points (such as viral load, transaminase normalization, etc.), though important, it has not been clearly studied how these intermediate results impact

Health Technology Assessment (HTA) Database.2004

1088. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation Shepherd J, Brodin H, Cave C, Waugh N (...) , Price A, Gabbay J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technology Assessment 2004; 8(39): 1-140 Authors' objectives

Health Technology Assessment (HTA) Database.2004

1089. Screening for hepatitis C virus infection

Screening for hepatitis C virus infection Screening for hepatitis C virus infection Screening for hepatitis C virus infection Chou R, Clark E, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chou R, Clark E, Helfand M. Screening for hepatitis C virus infection. Rockville: Agency for Healthcare Research and Quality (AHRQ (...) ). Preventive Services Task Force Systematic Evidence Review No. 24. 2004 Authors' objectives This report focuses on whether it is useful to order a hepatitis C virus (HCV) antibody test in either the general population of asymptomatic adults or selected high-risk subpopulations who have no history of liver disease or known liver function test abnormalities. Authors' conclusions Screening can detect chronic HCV infection. Antiviral treatment can successfully eradicate viremia, but data on long-term clinical

Health Technology Assessment (HTA) Database.2004

1090. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C National Institute for Clinical Excellence Citation National Institute for Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (...) . London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 75. 2004 Authors' objectives

To provide guidance on the use of interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C.

Authors' conclusions Guidance 1.1 Combination therapy with peginterferon alfa and ribavirin is recommended within its licensed indications for the treatment of people aged 18 years and over with moderate to severe chronic hepatitis C (CHC

Health Technology Assessment (HTA) Database.2004

1092. Dialysis for acute hepatic failure

Dialysis for acute hepatic failure Dialysis for acute hepatic failure We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Dialysis for acute hepatic failure Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by Alert This is a translation of version 1 published (...) on April 28, 2000. The latest version of this report is not available in English. To date, dialysis for acute hepatic failure has been tested on only a small number of patients in the world. Various dialysis methods for hepatic failure are intended to be used as a life supporting intervention while waiting for access to a liver suitable for transplantation. Without treatment, the patient would die within a few days. Currently there are three ways to perform liver dialysis. With albumin

Swedish Council on Technology Assessement2004

1093. Hepatitis C: Screening

Hepatitis C: Screening Screening: Hepatitis C Virus Infection U.S. Preventive Services Task Force Screening for Hepatitis C in Adults Release Date: March 2004 / Summary of Recommendation The USPSTF recommends against routine screening for hepatitis C virus (HCV) infection in asymptomatic adults who are not at increased risk (general population) for infection. Rating: . Rationale : The USPSTF found good evidence that screening with available tests can detect HCV infection in the general (...) . There is, as yet, no evidence that newer treatment regimens for HCV infection, such as pegylated interferon plus ribavirin, improve long-term health outcomes. There is limited evidence from non-U.S. studies that older therapies have some long-term health benefits for patients referred for treatment, but the generalizability of these results to the U.S. population is unknown. Of those infected with HCV, the proportion who progress to liver disease is uncertain. There is limited evidence that 10% to 20

Publication 3262004

1094. Hepatitis B Virus Infection: Screening

Hepatitis B Virus Infection: Screening Screening: Hepatitis B Virus Infection U.S. Preventive Services Task Force Screening for Hepatitis B Virus Infection Release Date: February 2004 / Summary of Recommendation The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit. Rating: . Rationale: The USPSTF found good evidence that universal prenatal screening for HBV infection using HBsAg (...) substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection. The current practice of vaccinating all infants against HBV infection and postexposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection. The USPSTF recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection. Rating: . Rationale

Publication 3262004

1095. BHIVA guidelines - HIV and chronic Hepatitis: co-infection with HIV and Hepatitis B virus infection

BHIVA guidelines - HIV and chronic Hepatitis: co-infection with HIV and Hepatitis B virus infection British HIV Association (BHIVA) HIV/HBV Coinfection Guidelines http://www.bhiva.org October 2004 1 BHIVA GUIDELINES - HIV AND CHRONIC HEPATITIS: CO-INFECTION WITH HIV AND HEPATITIS B VIRUS INFECTION, Updated October 2004 BHIVA Hepatitis Coinfection Guideline Committee on behalf of the British HIV Association. Contents 1.0 Key recommendations 2 1.1 Assessment of all HIV+ patients 2 1.2 Assessment (...) and management of HIV/HBV co-infected patients 2 1.3 Anti-HBV therapy in HIV/HBV co-infection 3 2.0 Audit standards 4 3.0 Background 4 3.1 Prevalence 4 3.2 Natural history 4 3.3 Immunisation 5 3.4 Delta virus 5 4.0 Assessment and investigations 6 4.1 Assessment 6 4.2 Investigations 6 4.2.1 Initial work-up 6 4.2.2 Additional tests 6 4.2.3 Follow-up tests 6 4.2.4 Test interpretation 6 4.2.5 Networks 7 5.0 Management 8 5.1 Hepatitis A vaccination 8 5.2 Transmission advice 8 5.3 General principles of hepatitis B

Publication 10832004

1096. BHIVA guidelines - HIV and chronic hepatitis: co-infection with HIV and Hepatitis C virus infection

BHIVA guidelines - HIV and chronic hepatitis: co-infection with HIV and Hepatitis C virus infection British HIV Association (BHIVA) HIV/HCV Coinfection Guidelines http://www.bhiva.org October 2004 1 BHIVA GUIDELINES - HIV AND CHRONIC HEPATITIS: CO-INFECTION WITH HIV AND HEPATITIS C VIRUS INFECTION Updated October 2004 BHIVA Hepatitis Coinfection Guideline Committee on behalf of the British HIV Association. Contents 1.0 Key recommendations 2 1.1 Assessment of all HIV+ patients 2 1.2 Assessment (...) 4.2.3 Liver biopsy 6 4.2.4 Networks 6 5.0 Management 7 5.1 General principles of Hepatitis C therapy 7 5.2 Who to treat 7 5.3 When to start treatment 8 5.4 Treatment options 8 5.4.1 Non-pegylated Interferon 8 5.4.2 Pegylated Interferon and ribavirin 8 5.4.2.1 APRICOT study 8 5.4.2.2 ACTG 5071 study 9 5.4.2.3 RIBAVIC study 9 5.4.3 Further information on anti-viral treatment 9 5.5 The interaction between ribavirin and anti-retroviral agents 9 5.6 Non-responders and relapsers 10 5.7 Acute Hepatitis C

Publication 10832004

1097. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. 15282351 2004 07 29 2004 08 06 2016 11 24 1533-4406 351 5 2004 Jul 29 The New England journal of medicine N. Engl. J. Med. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. 438-50 Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected (...) Study Group eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 0 Antiviral Agents 0 Hepatitis C Antibodies 0 Interferon-alpha 0 RNA, Viral 0 Recombinant Proteins 30IQX730WE Polyethylene Glycols 43K1W2T1M6 interferon alfa-2b 47RRR83SK7 interferon alfa-2a 49717AWG6K Ribavirin G8RGG88B68 peginterferon alfa-2b Q46947FE7K peginterferon alfa-2a AIM IM Curr Gastroenterol Rep. 2005 Feb;7(1):10

NEJM2004

1098. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. 15282352 2004 07 29 2004 08 06 2017 02 19 1533-4406 351 5 2004 Jul 29 The New England journal of medicine N. Engl. J. Med. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. 451-9 Chronic hepatitis C virus (HCV) infection is a cause of major complications in persons who are also infected (...) with the human immunodeficiency virus (HIV). However, the treatment of HCV infection in such persons has been associated with a high rate of intolerance and a low rate of response. We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV. A total of 66 subjects were randomly assigned to receive 180 microg of peginterferon alfa-2a weekly for 48 weeks, and 67 subjects were assigned to receive 6 million IU

NEJM2004 Full Text: Link to full Text with Trip Pro

1099. Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Lamivudine for patients with chronic hepatitis B and advanced liver disease. 15470215 2004 10 07 2004 10 12 2013 11 21 1533-4406 351 15 2004 Oct 07 The New England journal of medicine N. Engl. J. Med. Lamivudine for patients with chronic hepatitis B and advanced liver disease. 1521-31 The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. Patients with chronic hepatitis B who had histologically (...) confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring

NEJM2004

1100. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. 15371578 2004 09 16 2004 09 21 2016 11 24 1533-4406 351 12 2004 Sep 16 The New England journal of medicine N. Engl. J. Med. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. 1206-17 Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor (...) sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications. We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed

NEJM2004